Clinical Trials Directory

Trials / Terminated

TerminatedNCT04839601

RNS System RESPONSE Study

RNS® System Responsive Stimulation for Adolescents With Epilepsy Study

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
9 (actual)
Sponsor
NeuroPace · Industry
Sex
All
Age
12 Years – 17 Years
Healthy volunteers
Not accepted

Summary

To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.

Detailed description

NeuroPace is sponsoring the RESPONSE Study with the RNS System in individuals age 12 through 17 with partial (focal) onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures. For the purposes of this study, disabling seizures are defined as motor partial seizures, complex partial seizures, and/or secondarily generalized seizures. The RNS System is currently approved by the FDA for use in patients 18 years and older with hard-to-treat partial-onset seizures. The same device will be used in the RESPONSE Study. The study is a prospective open label single arm pivotal study and participants will be followed for 2 years after placement of the RNS System. The study will enroll a maximum of 200 subjects within the United States to ensure that at least 150 subjects are implanted with the RNS System. The study design includes one interim analysis which will occur after the 75th implanted patient reaches 12 months post-implant. If the study achieves its primary safety and effectiveness endpoint goals at the interim analysis, the study will be considered successful and enrollment will be stopped. If the interim analysis does not achieve the primary safety and effectiveness endpoint goals, the study will continue enrolling up to the maximum of 200 patients. A final analysis will be conducted after the 150th implanted patient reaches 12 months post-implant.

Conditions

Interventions

TypeNameDescription
DEVICERNS SystemThe RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.

Timeline

Start date
2021-10-27
Primary completion
2025-05-01
Completion
2025-05-01
First posted
2021-04-09
Last updated
2025-05-22

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04839601. Inclusion in this directory is not an endorsement.